The curriculum is divided into four modules, each focusing on essential aspects of pharmacological principles

February 2022 " InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined the company as VP Business Development. Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical industry. Carola Weiss ’ professional career brings deep expertise in business development, marketing & sales, licensing, alliance management, and strategic partnering. Her expertise guided numerous global negotiations, conclusions of partnership agreements, and fostered growth for her employers." Read more at the source #DrGPCR #GPCR #IndustryNews

February 2022 Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder "J an 27, 2022 07:00am Septerna wants to spark a second golden age in G-protein-coupled

GPCRs in Oncology and Immunology Esophageal and gastric cancer incidence trends in Golestan, Iran: An age-period-cohort We also fitted age-period-cohort (APC) models to assess nonlinear period and cohort effects as incidence There was a strong cohort effect for EC with a consistent decrease in the IRR across successive birth cohorts, starting with the oldest birth cohort (1924; IRR = 1.9 vs the reference birth cohort of 1947 ) through to the most recent cohort born in 1988 (IRR = 0.1).

GPCR Retreat Program < Back to schedule Using food perception and bioamine signaling networks to slow aging The Leiser laboratory is focused on the molecular mechanisms of aging, with an emphasis on stress response The lab works with multiple models, including Caenorhabditis elegans, in vitro tissue culture, and mice , to better understand the conserved mechanisms of aging.

< GPCR News < GPCRs in Oncology and Immunology Identification of S1PR4 as an immune modulator for favorable granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in a phase 1/2 trial of 81 adults aged Comparing outcomes using CLAG-M/sorafenib with those of a matched cohort of 76 patients treated with